Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
Bouchahda M, Boige V, Smith D, Karaboué A, Ducreux M, Hebbar M, Lepère C, Focan C, Guimbaud R, Innominato P, Awad S, Carvalho C, Tumolo S, Truant S, De Baere T, Castaing D, Rougier P, Morère JF, Taieb J, Adam R, Lévi F; ARTBC International. Bouchahda M, et al. Among authors: focan c. Eur J Cancer. 2016 Nov;68:163-172. doi: 10.1016/j.ejca.2016.09.011. Epub 2016 Oct 18. Eur J Cancer. 2016. PMID: 27768923
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Lévi F, Karaboué A, Saffroy R, Desterke C, Boige V, Smith D, Hebbar M, Innominato P, Taieb J, Carvalho C, Guimbaud R, Focan C, Bouchahda M, Adam R, Ducreux M, Milano G, Lemoine A. Lévi F, et al. Among authors: focan c. Br J Cancer. 2017 Sep 26;117(7):965-973. doi: 10.1038/bjc.2017.278. Epub 2017 Aug 17. Br J Cancer. 2017. PMID: 28817838 Free PMC article. Clinical Trial.
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Innominato PF, Ballesta A, Huang Q, Focan C, Chollet P, Karaboué A, Giacchetti S, Bouchahda M, Adam R, Garufi C, Lévi FA. Innominato PF, et al. Among authors: focan c. Cancer Med. 2020 Jun;9(12):4148-4159. doi: 10.1002/cam4.3056. Epub 2020 Apr 22. Cancer Med. 2020. PMID: 32319740 Free PMC article. Clinical Trial.
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.
Innominato PF, Karaboué A, Focan C, Chollet P, Giacchetti S, Bouchahda M, Ulusakarya A, Torsello A, Adam R, Lévi FA, Garufi C. Innominato PF, et al. Among authors: focan c. Int J Cancer. 2021 May 15;148(10):2512-2521. doi: 10.1002/ijc.33422. Epub 2020 Dec 10. Int J Cancer. 2021. PMID: 33270911 Free PMC article.
Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer.
Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, Lévi F, Bjarnason GA; Chronotherapy Group of the European Organization for Research and Treament of Cancer. Innominato PF, et al. Among authors: focan c. Cancer Res. 2009 Jun 1;69(11):4700-7. doi: 10.1158/0008-5472.CAN-08-4747. Cancer Res. 2009. PMID: 19470769 Free PMC article. Clinical Trial.
Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.
Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, Iacobelli S, Tampellini M, Durando X, Mormont MC, Waterhouse J, Lévi FA. Innominato PF, et al. Among authors: focan c. Int J Cancer. 2012 Dec 1;131(11):2684-92. doi: 10.1002/ijc.27574. Epub 2012 Jul 3. Int J Cancer. 2012. PMID: 22488038 Free article. Clinical Trial.
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, Focan C, Garufi C, Iacobelli S, Tampellini M, Tumolo S, Carvalho C, Karaboué A, Poncet A, Spiegel D, Lévi F; International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group. Innominato PF, et al. Among authors: focan c. Cancer. 2013 Jul 15;119(14):2564-73. doi: 10.1002/cncr.28072. Epub 2013 Apr 30. Cancer. 2013. PMID: 23633399 Free article.
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
Lévi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C. Lévi F, et al. Among authors: focan c. Cancer. 1999 Jun 15;85(12):2532-40. doi: 10.1002/(sici)1097-0142(19990615)85:12<2532::aid-cncr7>3.0.co;2-1. Cancer. 1999. PMID: 10375099 Clinical Trial.
192 results